Burning Rock Biotech (NASDAQ:BNR) Stock Rating Upgraded by Wall Street Zen

Burning Rock Biotech (NASDAQ:BNR) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised Burning Rock Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Burning Rock Biotech Price Performance

Shares of NASDAQ:BNR opened at $11.82 on Friday. Burning Rock Biotech has a 12-month low of $6.79 and a 12-month high of $41.72. The stock has a market cap of $124.35 million, a PE ratio of -13.59 and a beta of 1.29. The business has a 50 day moving average of $13.12 and a 200-day moving average of $12.63.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Thursday, September 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $19.84 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative return on equity of 12.98% and a negative net margin of 13.60%.

Institutional Trading of Burning Rock Biotech

A hedge fund recently raised its stake in Burning Rock Biotech stock. Renaissance Technologies LLC grew its holdings in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 13.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,407 shares of the company’s stock after purchasing an additional 4,290 shares during the period. Renaissance Technologies LLC owned about 0.34% of Burning Rock Biotech worth $571,000 at the end of the most recent quarter. 30.03% of the stock is owned by institutional investors and hedge funds.

About Burning Rock Biotech

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy.

Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.